Monitoring progression in Friedreich ataxia (FRDA): The use of clinical scales

Journal of Neurochemistry

Volumn 126, Issue SUPPL.1, 2013, Pages 118-124

  Bürk, Katrin ^a,b   Schulz, Stefanie R ^b   Schulz, Jörg B ^b,c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

ataxia; FRDA; scales

Indexed keywords

CLINICAL ASSESSMENT TOOL; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; FRIEDREICH ATAXIA; FRIEDREICH ATAXIA RATING SCALE; HUMAN; INTERMETHOD COMPARISON; INTERNAL CONSISTENCY; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; INTERRATER RELIABILITY; INTRARATER RELIABILITY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCALE FOR THE ASSESSMENT AND RATING OF ATAXIA; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ATAXIA; FRDA; SCALES;

ALGORITHMS; ATAXIA; DISEASE PROGRESSION; FRIEDREICH ATAXIA; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 84880373397     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12318     Document Type: Review

References (40)

1. Artuch R., Aracil A., Mas A., Colomé C., Rissech M., Monrõs E., and, Pineda M., (2002) Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33, 190-193.
2. Bier J. C., Dethy S., Hildebrand J., Jacquy J., Manto M., Martin J. J., and, Seeldrayers P., (2003) Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J. Neurol. 250, 693-697.
3. Boesch S., Sturm B., Hering S., Goldenberg H., Poewe W., and, Scheiber-Mojdehkar B., (2007) Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann. Neurol. 62, 521-524.
4. Broccoletti T., Del Giudice E., Cirillo E., Vigliano I., Giardino G., Ginocchio V. M., Bruscoli S., Riccardi C., and, Pignata C., (2011) Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur. J. Neurol. 18, 564-570.
5. Bürk K., Mälzig U., Wolf S., et al,. (2009) Comparison of three clinical rating scales in Friedreich ataxia (FA). Mov. Disord. 24, 1779-1784.
6. Bürk K., Wolf S., Heck S., et al,. (2011) Do clinical rating scales reflect progression in Friedreich ataxia (FA)? Presented at the FARA scientific symposium on Friedreich's ataxia. 4th International FA Conference Abstracts, Illkirch. Online at http://www.curefa.org/-pdf/ 4thInternationalFAConferenceAbstracts.pdf.
7. Cano S. J., Hobart J. C., Hart P. E., Korlipara L. V., Schapira A. H., and, Cooper J. M., (2005) International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Mov. Disord. 20, 1585-1591.
8. Cooper J. M., Korlipara L. V., Hart P. E., and, Schapira A. H., (2008) Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol. 15, 1371-1379.
9. Cutter G. R., Baier M. L., Rudick R. A., et al,. (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871-882.
10. Di Prospero N. A., Baker A., Jeffries N., and, Fischbeck K. H., (2007) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 6, 878-886.
11. Fahey M. C., Corben L., Collins V., Churchyard A. J., and, Delatycki M. B., (2000) How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. J. Neurol. Neurosurg. Psychiatry 78, 411-413.
12. Gabsi S., Gouider-Khouja N., Belal S., Fki M., Kefi M., Turki I., Ben Hamida M., Kayden, H., Mebazaa R., and, Hentati F., (2001) Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur. J. Neurol. 8, 477-481.
13. Gazulla J., and, Benavente I., (2007) Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy. Acta Neurol. Scand. 116, 235-238.
14. Hassin-Baer S., Korczyn A. D., and, Giladi N., (2000) An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment. J. Neural Transm. 107, 1187-1189.
15. Heo J. H., Lee S. T., Chu K., and, Kim M., (2008) The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J. Neurol. Sci. 271, 87-90.
16. Keith R. A., Granger C. V., Hamilton B. B., and, Sherwin F. S., (1987) The functional independence measure: a new tool for rehabilitation. Adv. Clin. Rehabil. 1, 6-18.
17. Kimura N., Kumamoto T., Masuda T., Nomura Y., Hanaoka T., Hazama Y., Okazaki T., and, Arakawa R., (2009) Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT. J. Neurol. Sci. 281, 93-98.
18. Kimura N., Kumamoto T., Masuda T., Nomura Y., Hanaoka T., Hazama Y., and, Okazaki T., (2011) Evaluation of the effects of thyrotropin releasing hormone (TRH) therapy on regional cerebral blood flow in the cerebellar variant of multiple system atrophy using 3DSRT. J. Neuroimaging 21, 132-137.
19. Likert R., (1932) A technique for the measurement of attitudes. Arch. Psychol. 140, 5-53.
20. Löhle M., Schrempf W., Wolz M., Reichmann H., and, Storch A., (2008) Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2-a video case report. Mov. Disord. 23, 1314-1316.
21. Lynch D. R., Farmer J. M., Tsou A. Y., et al,. (2006) Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology 66, 1711-1716.
22. Lynch D. R., Perlman S. L., and, Meier T., (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch. Neurol. 67, 941-947.
23. Lynch D. R., Pandolfo M., Schulz J. B., et al,. (2013) Common data elements for clinical research in Friedreich's ataxia. Mov. Disord. 28, 190-195. doi: 10.1002/mds.25201. Epub 2012 Dec 12.
24. Meier T., Perlman S. L., Rummey C., Coppard N. J., and, Lynch D. R., (2012) Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J. Neurol. 259, 284-291.
25. Metz G., Coppard N., Cooper J. M., et al,. (2013) Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain 136, 259-268.
26. Mori M., Adachi Y., Mori N., Kurihara S., Kashiwaya Y., Kusumi M., Takeshima T., and, Nakashima K., (2002) Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration. J. Neurol. Sci. 195, 149-152.
27. Nakamura K., Yoshida K., Miyazaki D., Morita H., and, Ikeda S., (2009) Spinocerebellar ataxia type 6 (SCA6): clinical pilot trial with gabapentin. J. Neurol. Sci. 278, 107-111.
28. Pineda M., Arpa J., Montero R., et al,. (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: Long-term follow-up. Eur. J. Paediatr. Neurol. 12, 470-475.
29. Pineda M., Montero R., Aracil A., et al,. (2010) Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up. Mov. Disord. 25, 1262-1268.
30. Ristori G., Romano S., Visconti A., Cannoni S., Spadaro M., Frontali M., Pontieri F. E., Vanacore N., and, Salvetti M., (2010) Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74, 839-845.
31. Ritvo P. G., Fisher J. S., Miller D. M., et al,. (1997) Multiple Sclerosis Quality of Life Inventory (MSQLI): A User′s Manual. National Multiple Sclerosis Society, New York.
32. Schmitz-Hübsch T., du Montcel S. T., Baliko L., et al,. (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66, 1717-1720.
33. Schmitz-Hübsch T., Coudert M., Bauer P., et al,. (2008) Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 71, 982-989.
34. Schmitz-Hübsch T., Fimmers R., Rakowicz M., et al,. (2010) Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 74, 678-684.
35. Shah S., Vanclay F., and, Cooper B., (1989) Improving the sensitivity of the Barthel Index for stroke rehabilitation. J. Clin. Epidemiol. 42, 703-709.
36. Storey E., Tuck K., Hester R., Hughes A., and, Churchyard A., (2004) Inter-rater reliability of the International Cooperative Ataxia Rating Scale (ICARS). Mov. Disord. 19, 190-192.
37. Subramony S. H., May W., Lynch D., et al,. (2005) Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64, 1261-1262.
38. Trouillas P., Takayanagi T., Hallett M., et al,. (1997) International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. 12, 205-211.
39. Weyer A., Abele M., Schmitz-Hübsch T., Schoch B., Frings M., Timmann D., and, Klockgether T., (2007) Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov. Disord. 22, 1633-1637.
40. Zesiewicz T. A., Greenstein P. E., Sullivan K. L., Wecker L., Miller A., Jahan I., Chen R., and, Perlman S. L., (2012) A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 78, 545-550.